Primary Care Diabetes
Volume 4 , Pages S19-S23 , April 2010

Basal insulins: Pharmacological properties and patient perspectives

  • Martin J. Abrahamson

      Affiliations

    • Corresponding Author InformationCorrespondence: Martin J Abrahamson, MD FACP. Chief Medical Officer and Senior Vice President, Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, USA. Tel: +1 617 732 2501; fax: +1 617 732 2574

References 

  1. Barnett A . Dosing of insulin glargine in the treatment of type 2 diabetes . Clin. Ther. . 2007;29:987–999
  2. Holman RR , Paul SK , Bethel MA , et al.   10-year follow-up of intensive glucose control in type 2 diabetes . N. Engl. J Med. . 2008;359:1577–1589
  3. UK Prospective Diabetes Study (UKPDS) Group  . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) . Lancet . 1998;352:837–853
  4. Home P . The challenge of poorly controlled diabetes mellitus . Diabetes Metab. . 2003;29:101–109
  5. Nathan DM , Buse JB , Davidson MB , et al.   Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes . Diabetologia . 2009;52:17–30
  6. van Avendonk MJP , Gorter KJ , van den Donk M , Rutten GEHM . Insulin therapy in type 2 diabetes is no longer a secondary care activity in the Netherlands . Prim. Care Diabetes . 2009;3:23–28
  7. Bazzano LA , Lee LJ , Shi L , et al.   Safety and efficacy of glargine compared with NPH insulin for the treatment of type 2 diabetes: a meta-analysis of randomized controlled trials . Diabet. Med. . 2008;25:924–932
  8. Selam J-L , Koenen C , Weng W , Meneghini L . Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study . Curr. Med. Res. Opin. . 2008;24:11–20
  9. Riddle MC , Rosenstock J , Gerich J , on behalf of the INsulin Glargine 4002 Study Investigators  . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients . Diabetes Care . 2003;26:3080–3086
  10. Horvath K , Jeitler K , Berghold A , et al.   Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus . Cochrane Database Syst. Rev. . 2007; CD005613.
  11. Peyrot M , Skovlund SE , Landgraf R . Epidemiology and correlates of weight worry in the multinational Diabetes Attitudes, Wishes and Needs study . Curr. Med. Res. Opin. . 2009;25:1985–1993
  12. Kurtzhals P . How to achieve a predictable basal insulin? . Diabetes Metab. . 2005;31:4S25; 4S33
  13. Polonsky KS , Given BD , van Cauter E . Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects . J. Clin. Invest. . 1988;81:442–448
  14. Lepore M , Pampanelli S , Fanelli C , et al.   Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro . Diabetes . 2000;49:2142–2148
  15. Scholtz HE , Pretorius SG , Wessels DH , Becker RHA . Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique . Diabetologia . 2005;48:1988–1995
  16. Plank J , Bodenlenz M , Sinner F , et al.   A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir . Diabetes Care . 2005;28:1107–1112
  17. Klein O , Lynge J , Endahl L , et al.   Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes . Diabetes Obes. Metab. . 2007;9:290–299
  18. Philis-Tsimikas A , Charpentier G , Clauson P , et al.   Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes . Clin. Ther. . 2006;28:1569–1581
  19. Hermansen K , Davies M , Derezinski T , et al.   A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes . Diabetes Care . 2006;29:1269–1274
  20. Rosenstock J , Davies M , Home PD , et al.   A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes . Diabetologia . 2008;51:408–416
  21. Meneghini L , Koenen C , Weng W , Selam J-L . The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes – results of the randomized, controlled PREDICTIVE™ 303 study . Diabetes Obes. Metab. . 2007;9:902–913
  22. Blonde L , Merilainen M , Karwe V , et al.   Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets – the TITRATE™ study . Diabetes Obes. Metab. . 2009;11:623–631
  23. Davies M , Lavalle-González F , Storms F , Gomis R , AT.LANTUS Study Group  . Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial . Diabetes Obes. Metab. . 2008;10:387–399

PII: S1751-9918(10)60005-8

doi: 10.1016/S1751-9918(10)60005-8

Primary Care Diabetes
Volume 4 , Pages S19-S23 , April 2010

Article Tools